Komori
Nippon Shinyaku (4516) · FactRestated

Two-pillar business structure: pharmaceuticals and functional foods

First written in FY2016. 22 of 23 entries say "Restated". Latest entry: FY2025-H1.

23entries
9years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY2025-H12016: 120162017: 220172018: 320182019: 320192020: 320202021: 420212022: 220222023: 320232024: 22024
Same theme, other companies
Two-business-segment structure comprising Food and PharmaceuticalsA theme 2 companies write about · 0 as a headwind · 0 as a tailwind

1 other company's latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2025-H1RestatedAnnual report

    「There were no significant changes in the nature of the businesses conducted by our group (the Company and its affiliates) during the current interim consolidated accounting period. There were also no changes among the principal affiliates.」

    There have been no material changes to the business activities centered on the pharmaceuticals and functional foods businesses or to the principal affiliated companies.
  2. FY2024-Q3RestatedAnnual report

    「There were no material changes in the nature of the businesses conducted by the Group (the Company and its affiliates) during the cumulative third quarter of the current consolidated fiscal year. There were also no changes among the principal affiliates.」

    There have been no material changes to the business activities centered on the pharmaceuticals and functional foods businesses or to the principal affiliated companies.
  3. FY2024-Q2RestatedAnnual report

    「There were no material changes in the nature of the businesses conducted by the Group (the Company and its affiliates) during the cumulative second quarter of the current consolidated fiscal year. There were also no changes among the principal affiliates.」

    There have been no material changes to the business structure centered on the pharmaceuticals and functional foods businesses or to the principal affiliated companies.
  4. FY2024-Q1RestatedAnnual report

    「There were no material changes in the nature of the businesses conducted by the Group (the Company and its affiliates) during the cumulative first quarter of the current consolidated fiscal year. There were also no changes among the principal affiliates.」

    There have been no material changes to the business activities centered on the pharmaceuticals and functional foods businesses or to the principal affiliated companies.
  5. FY2023RestatedAnnual report

    「The Group consists of the Company and 6 consolidated subsidiaries, and its principal business is the manufacture and sale of pharmaceuticals and functional foods.」

    This reconfirms the Group structure, including 6 consolidated subsidiaries, and the business structure centered on pharmaceuticals and functional foods.
  6. FY2023-Q2RestatedAnnual report

    「There were no material changes in the nature of the businesses conducted by the Group (the Company and its affiliates) during the cumulative second quarter of the current consolidated fiscal year. There were also no changes among the principal affiliates.」

    There have been no material changes to the business structure centered on the pharmaceuticals and functional foods businesses or to the principal affiliated companies.
  7. FY2022-Q3RestatedAnnual report

    「There were no material changes in the nature of the businesses conducted by the Group (the Company and its affiliates) during the cumulative third quarter of the current consolidated fiscal year. There were also no changes among the principal affiliates.」

    There have been no material changes to the business activities centered on the pharmaceuticals and functional foods businesses.
  8. FY2022-Q2RestatedAnnual report

    「There were no material changes in the nature of the businesses conducted by the Group (the Company and its affiliates) during the cumulative second quarter of the current consolidated fiscal year. There were also no changes among the principal affiliates.」

    There have been no material changes to the business activities centered on the pharmaceuticals and functional foods businesses.
  9. FY2022-Q1RestatedAnnual report

    「There were no material changes in the nature of the businesses conducted by the Group (the Company and its affiliates) during the cumulative first quarter of the current consolidated fiscal year. There were also no changes among the principal affiliates.」

    There have been no material changes to the business structure centered on the pharmaceuticals and functional foods businesses or to the principal affiliated companies.
  10. FY2021RestatedAnnual report

    「The Group consists of the Company and 4 consolidated subsidiaries, and its principal business is the manufacture and sale of pharmaceuticals and functional foods.」

    This reconfirms the two-business structure centered on pharmaceuticals and functional foods.
  11. FY2021-Q3RestatedAnnual report

    「There were no material changes in the nature of the businesses conducted by the Group (the Company and its affiliates) during the cumulative third quarter of the current consolidated fiscal year. There were also no changes among the principal affiliates.」

    There have been no material changes to the business structure centered on the pharmaceuticals and functional foods businesses or to the principal affiliated companies.
  12. FY2021-Q2RestatedAnnual report

    「There were no material changes in the nature of the businesses conducted by the Group (the Company and its affiliates) during the cumulative second quarter of the current consolidated fiscal year. There were also no changes among the principal affiliates.」

    There have been no material changes to the business structure centered on the pharmaceuticals and functional foods businesses or to the principal affiliated companies.
  13. FY2021-Q1RestatedAnnual report

    「There were no material changes in the nature of the businesses conducted by the Group (the Company and its affiliates) during the cumulative first quarter of the current consolidated fiscal year. There were also no changes among the principal affiliates.」

    There have been no material changes to the business structure centered on the pharmaceuticals and functional foods businesses or to the principal affiliated companies.
  14. FY2020-Q3RestatedAnnual report

    「There were no material changes in the nature of the businesses conducted by the Group (the Company and its affiliates) during the cumulative third quarter of the current consolidated fiscal year. There were also no changes among the principal affiliates.」

    There have been no material changes to the business structure centered on the pharmaceuticals and functional foods businesses or to the principal affiliated companies.
  15. FY2020-Q2RestatedAnnual report

    「There were no material changes in the nature of the businesses conducted by the Group (the Company and its affiliates) during the cumulative second quarter of the current consolidated fiscal year. There were also no changes among the principal affiliates.」

    There have been no material changes to the business structure centered on the pharmaceuticals and functional foods businesses or to the principal affiliated companies.
  16. FY2020-Q1RestatedAnnual report

    「There were no material changes in the nature of the businesses conducted by the Group (the Company and its affiliates) during the cumulative first quarter of the current consolidated fiscal year. There were also no changes among the principal affiliates.」

    There have been no material changes to the business structure centered on the pharmaceuticals and functional foods businesses or to the principal affiliated companies.
  17. FY2019-Q3RestatedAnnual report

    「There were no material changes in the nature of the businesses conducted by the Group (the Company and its affiliates) during the cumulative third quarter of the current consolidated fiscal year. There were also no changes among the principal affiliates.」

    There have been no material changes to the business structure centered on the pharmaceuticals and functional foods businesses or to the principal affiliated companies.
  18. FY2019-Q2RestatedAnnual report

    「There were no material changes in the nature of the businesses conducted by the Group (the Company and its affiliates) during the cumulative second quarter of the current consolidated fiscal year. There were also no changes among the principal affiliates.」

    There have been no material changes to the business structure centered on the pharmaceuticals and functional foods businesses or to the principal affiliated companies.
  19. FY2019-Q1RestatedAnnual report

    「There were no material changes in the nature of the businesses conducted by the Group (the Company and its affiliates) during the cumulative first quarter of the current consolidated fiscal year. There were also no changes among the principal affiliates.」

    There have been no material changes to the business structure centered on the pharmaceuticals and functional foods businesses or to the principal affiliated companies.
  20. FY2018-Q3RestatedAnnual report

    「There were no material changes in the nature of the businesses conducted by the Group (the Company and its affiliates) during the cumulative third quarter of the current consolidated fiscal year. There were also no changes among the principal affiliates.」

    There have been no material changes to the business structure centered on the pharmaceuticals and functional foods businesses or to the principal affiliated companies.
  21. FY2018-Q2RestatedAnnual report

    「There were no material changes in the nature of the businesses conducted by the Group (the Company and its affiliates) during the cumulative second quarter of the current consolidated fiscal year. There were also no changes among the principal affiliates.」

    There have been no material changes to the business structure centered on the pharmaceuticals and functional foods businesses or to the principal affiliated companies.
  22. FY2018-Q1RestatedAnnual report

    「There were no material changes in the nature of the businesses conducted by the Group (the Company and its affiliates) during the cumulative first quarter of the current consolidated fiscal year. There were also no changes among the principal affiliates.」

    There have been no material changes to the business structure centered on the pharmaceuticals and functional foods businesses or to the principal affiliated companies.
  23. FY2016First statedAnnual report

    「The Group consists of the Company, 3 consolidated subsidiaries and 1 non-consolidated subsidiary, and its principal business is the manufacture and sale of pharmaceuticals and functional foods.」

    The reportable segments are the pharmaceuticals business and the functional foods business.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Nippon Shinyaku's next results are scheduled for 2026-11-13. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.